HBOT research for mild-to-moderate TBI and persistent post-concussive symptoms. Hadanny & Efrati 2020 showed significant cognitive improvement at 2.0 ATA.
Quality: Moderate Weak recommendation
Efrati Lab RCTs (Boussi-Gross 2013, Tal 2017) show consistent benefit at 2.0 ATA. DoD HOPPS trials negative but with sham pressure confound. UHMS review pending.
Hyperbaric oxygen therapy has been studied extensively for traumatic brain injury. The leading research group (Efrati Lab, Tel Aviv) has published multiple RCTs showing significant cognitive and quality-of-life improvements in mild-to-moderate TBI patients treated with 40–60 sessions at 2.0 ATA. Results suggest HBOT induces neuroplasticity and improves cerebral blood flow in injured regions.
HBOT addresses TBI through several overlapping mechanisms. Elevated arterial oxygen tension at 2.0 ATA drives dissolved-plasma oxygen delivery to chronically hypoperfused brain regions, bypassing the compromised vascular supply. Repeated intermittent hyperoxia paradoxically stabilises HIF-1α, triggering downstream angiogenesis and the formation of new capillary networks in damaged tissue. HBOT also reduces microglial activation and shifts macrophage polarisation toward the reparative M2 phenotype, dampening the chronic neuroinflammation characteristic of post-TBI brains. Mitochondrial biogenesis and oxidative phosphorylation efficiency improve, supporting the metabolic demands of surviving neurons. SPECT and perfusion MRI imaging in Efrati Lab trials consistently show increased cerebral blood flow in previously hypoperfused areas corresponding to clinical gains.
| Typical protocol | 40–60 sessions at 2.0 ATA, 90 minutes each, 5 days/week |
|---|---|
| Evidence level | Multiple RCTs — Moderate evidence, UHMS review pending |
| FDA / regulatory status | Not FDA-approved; studied off-label |
The Efrati Lab 2.0 ATA / 40–60 session protocol is the most-studied TBI course. Sessions include compression over 10–15 minutes, 60–90 minutes at depth with scheduled 5-minute air breaks every 20–30 minutes, and 10–15 minute decompression. Daily attendance for approximately 8–12 weeks. Pre-treatment screening includes neurocognitive baseline testing (ANAM, CNS Vital Signs, or domain-specific batteries), optional SPECT or perfusion MRI imaging, and standard HBOT medical screening. Interim assessment at session 20 and post-course assessment at 1–3 months.